“UCD spinout drug company Atxa Therapeutics, which is developing novel therapies that tackle a deadly heart condition, is seeking to raise $30 million to bring its treatment through clinical trials and secure regulatory approval …” (more)
[Ciarán Hancock, Irish Times, 27 July]
Tags: spin-outs, UCD
This entry was posted on Monday, July 27th, 2020 at 09:44 and is filed under Research.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
